About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 272 record(s)
Req # A-2021-001228
Adverse Drug Reaction (ADR) for LEVOMEPROMAZINE. Report number: E2B_03452251.Organization: Health Canada
February 2022
Req # A-2021-001230
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_03888567, E2B_03523424, E2B_03997152, 000929634, E2B_04063204, 000934682, E2B_03698040, 000933246, E2B_03746706.Organization: Health Canada
February 2022
Req # A-2021-001266
Adverse Drug Reactions (ADRs) for TRIAMCINOLONE ACETONIDE. Report numbers: E2B_03537189; E2B_03518325, E2B_03530108; 000940010; E2B_03676035; E2B_03669243.Organization: Health Canada
February 2022
Req # A-2021-001273
Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_03543490, E2B_03844106, E2B_03535699, E2B_03872641, E2B_03840947, E2B_03532975, E2B_03844380, E2B_03844638, E2B_03847954, E2B_03924217, E2B_03611178, E2B_03645079.Organization: Health Canada
February 2022
Req # A-2021-001285
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-101998-768.Organization: Health Canada
February 2022
Req # A-2021-001305
Adverse Drug Reactions (ADRs) for DEXILANT. Report numbers: E2B_04319692, E2B_04341965, E2B_04337795, E2B_04319484, 953112, E2B_04241092, E2B_04336040. ADRs for VEDOLIZUMAB. Report numbers: 956571, 963242, E2B_04309896, ADR for IXAZOMIB. Report number: E2B_04350794. ADRs for ONDANSETRON. Report numbers: 953766, 952157, 954222, E2B_04354907. ADRs for GAMMAGARD LIQUID. Report numbers: 952532, 952540, 952204.Organization: Health Canada
February 2022
Req # A-2021-001329
Adverse Drug Reactions (ADRs). Report numbers: E2B_03396786, E2B_03763139, E2B_03404401, 000911046, 000911688, 000913196, 000923613, 000938367, E2B_03454185, E2B_03073406, E2B_03198395, 000919529, 000920229, E2B_03022085, E2B_03043699, E2B_03170465, E2B_03278533, E2B_03303420, E2B_03321055, E2B_03547292.Organization: Health Canada
February 2022
Req # A-2021-001345
Adverse Drug Reaction (ADR) for FUROSEMIDE. Report number: E2B 03482529.Organization: Health Canada
February 2022
Req # A-2021-001347
Adverse Drug Reaction (ADR) for INFLUENZA VACCINE. Report number: E2B_03813844.Organization: Health Canada
February 2022
Req # A-2021-001393
Adverse Drug Reactions (ADRs). Report numbers: E2B_03187411, E2B_03848638, E2B_00948569, E2B_03511582.Organization: Health Canada
February 2022